Drug intelligence / Profile preview

TCRαβ KO T-cells

Development stage: Unknown
Lead developer: Cellectis
Modality: Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

TCRαβ KO T-cells are allogeneic T-cells derived from healthy donors, genetically engineered using TALEN® technology to disrupt the T-cell receptor alpha-beta (TCRαβ) complex. This modification prevents the cell surface expression of the TCRαβ, thereby minimizing the risk of graft-versus-host disease (GvHD) in allogeneic settings. In the provided context, these cells serve as a control, being non-transduced with a Chimeric Antigen Receptor (CAR), distinguishing them from the therapeutic product UCART123 which incorporates this TCRαβ knockout feature.

Other names: TCRαβ-deficient T-cellsTCRαβneg T cells

Targets

TCR (T cell antigen receptor complex)CD52 (CD52 Antigen)

Beyond the preview

Go deeper on TCRαβ KO T-cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCRαβ KO T-cells.

Explore the full profile